Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease.
Bovine CuZnSOD was used during an 8-year period as an anti-inflammatory drug in 26 patients with severe Crohn's disease, usually after failure of corticotherapy, or when this drug was avoided because of side-effects or abscesses. This was a Phase II trial during which doses, routes of administration and concomitant therapies were progressively modified. The acceptability was excellent with the free enzyme. We obtained 19/26 very good short term responses, and 82% good results on long term evolution. The efficacy of SOD as an anti-inflammatory drug in Crohn's disease needs to be confirmed by controlled trials.
Emerit
J
J
Service de Médecine Interne, Hôpital de la Salpétrière, Paris, France.
Pelletier
S
S
Tosoni-Verlignue
D
D
Mollet
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy*; D003676:Deferoxamine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013482:Superoxide Dismutase / Q000009:adverse effects / Q000627:therapeutic use*
D013482:Superoxide Dismutase; D003676:Deferoxamine